Drug intelligence / Profile preview

amoxicillin + clavulanic acid + fluconazole + levofloxacin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of four pharmaceutical agents—amoxicillin, clavulanic acid, fluconazole, and levofloxacin. - **Amoxicillin** is a penicillin-class antibiotic that inhibits bacterial cell wall synthesis. - **Clavulanic acid** is a beta-lactamase inhibitor that protects amoxicillin from degradation by beta-lactamase enzymes produced by resistant bacteria[1][2][3][4][5][6]. - **Fluconazole** is an antifungal agent (not described in the provided search results but widely known) that inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis and thus fungal cell membrane formation. - **Levofloxacin** is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, essential for DNA replication and repair[7][10]. This combination would provide broad antibacterial coverage (including Gram-positive and Gram-negative bacteria) as well as antifungal activity. There are no known approved or marketed products containing all four agents together; such combinations may be used in specific clinical scenarios under medical supervision.

02

Targets

Topo IV (Bacterial Topoisomerase IV)CYP51A1 (Sterol 14α-demethylase)DNA gyraseβ-lactamasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amoxicillin + clavulanic acid + fluconazole + levofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clavulanic acid + fluconazole + levofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call